In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v...

Descripción completa

Detalles Bibliográficos
Autores principales: Ripamonti, M., Pezzoni, G., Pesenti, E., Pastori, A., Farao, M., Bargiotti, A., Suarato, A., Spreafico, F., Grandi, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977399/
https://www.ncbi.nlm.nih.gov/pubmed/1586598
_version_ 1782135253198962688
author Ripamonti, M.
Pezzoni, G.
Pesenti, E.
Pastori, A.
Farao, M.
Bargiotti, A.
Suarato, A.
Spreafico, F.
Grandi, M.
author_facet Ripamonti, M.
Pezzoni, G.
Pesenti, E.
Pastori, A.
Farao, M.
Bargiotti, A.
Suarato, A.
Spreafico, F.
Grandi, M.
author_sort Ripamonti, M.
collection PubMed
description FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v. or oral route. The pattern of anti-tumour activity of FCE 23762 differs from that of doxorubicin in maintaining anti-tumour activity against two P388 murine leukaemia sublines resistant to doxorubicin and, although at borderline levels of efficacy, against LoVo human colon adenocarcinoma resistant to doxorubicin. FCE 23762 exhibits remarkable efficacy against MX-1 human mammary carcinoma, with most treated mice being cured both after i.v. and oral treatment. Anti-tumour activity was also observed against L1210 murine leukaemia and two sublines resistant to cis-platinum and melphalan, M5076 murine reticulosarcoma, MTV murine mammary carcinoma and N592 human small cell lung cancer.
format Text
id pubmed-1977399
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19773992009-09-10 In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Ripamonti, M. Pezzoni, G. Pesenti, E. Pastori, A. Farao, M. Bargiotti, A. Suarato, A. Spreafico, F. Grandi, M. Br J Cancer Research Article FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v. or oral route. The pattern of anti-tumour activity of FCE 23762 differs from that of doxorubicin in maintaining anti-tumour activity against two P388 murine leukaemia sublines resistant to doxorubicin and, although at borderline levels of efficacy, against LoVo human colon adenocarcinoma resistant to doxorubicin. FCE 23762 exhibits remarkable efficacy against MX-1 human mammary carcinoma, with most treated mice being cured both after i.v. and oral treatment. Anti-tumour activity was also observed against L1210 murine leukaemia and two sublines resistant to cis-platinum and melphalan, M5076 murine reticulosarcoma, MTV murine mammary carcinoma and N592 human small cell lung cancer. Nature Publishing Group 1992-05 /pmc/articles/PMC1977399/ /pubmed/1586598 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ripamonti, M.
Pezzoni, G.
Pesenti, E.
Pastori, A.
Farao, M.
Bargiotti, A.
Suarato, A.
Spreafico, F.
Grandi, M.
In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title_full In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title_fullStr In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title_full_unstemmed In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title_short In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
title_sort in vivo anti-tumour activity of fce 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977399/
https://www.ncbi.nlm.nih.gov/pubmed/1586598
work_keys_str_mv AT ripamontim invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT pezzonig invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT pesentie invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT pastoria invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT faraom invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT bargiottia invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT suaratoa invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT spreaficof invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells
AT grandim invivoantitumouractivityoffce23762amethoxymorpholinylderivativeofdoxorubicinactiveondoxorubicinresistanttumourcells

Ejemplares similares